Efficacy and safety of CD19-targeted CAR T-cells for relapsed/refractory ALL

At the 20th Congress of the European Hematology Association (EHA), Dieter Hoelzer, MD, PhD, of Goethe University Hospital, Frankfurt, Germany, discusses the outcomes of clinical trials evaluating treatment using chimeric antigen receptor (CAR)-modified T-cells with specificity for CD19 for adult and pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL).

Share this video  
Similar topics